Global Botulinum Toxin Market, By Type (Botulinum Toxin A and Botulinum Toxin B), Application (Aesthetic and Therapeutic), End User (Dermatology Centers, Hospitals and Clinics and Others) – Industry Trends and Forecast to 2030.
Botulinum Toxin Market Analysis and Size
The growing cases of fitfulness, cervical dystonia, chronic megrim, a surge in demand for botulinum toxin, and rising product launches and approvals are doubtless to drive the expansion of the botulinum toxin throughout the forecast amount. However, the adverse effects of botulinum and poor compensation policies are anticipated to limit market growth over the forecast amount.
Data Bridge Market Research analyses that the botulinum toxin market will rocket up to USD 7,929.14 million by 2030 and is expected to undergo a CAGR of 6.43% during the forecast period. The botulinum toxin type A segment significantly generated revenue in 2021 and is expected to maintain its dominance in the forecast period. This can be attributed to the increasing customer preference for its benefits, such as minimal pain, absence of blood loss, and lack of scarring during the procedure. Moreover, the market growth is further fuelled by the growing utilization of botulinum toxin type A in treating chronic migraine, tension-type headaches, and other primary neurological disorders. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Botulinum Toxin Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Botulinum Toxin A and Botulinum Toxin B), Application (Aesthetic and Therapeutic), End User (Dermatology Centers, Hospitals and Clinics, and Others) |
|
Countries Covered |
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America. |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc (U.K.), Medtronic (Ireland), ALLERGAN (Dublin, Ireland), Pfizer Inc (U.S.), Ipsen Pharma (France), UCB Pharma Ltd (U.K.), Sanofi (France), INMED PHARMACEUTICALS INC (Canada), Taj Pharmaceuticals Limited (India), Johnson & Johnson Services, Inc (U.S.), MediciNova, Inc (U.S.), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Merz Pharma (Germany), GW Pharmaceuticals plc (U.K.), Revance Therapeutics, Inc (U.S.), Acorda Therapeutics, Inc (U.S.), and HUGEL, Inc. (South Korea) among other |
|
Market Opportunities |
|
Market Definition
Botulinum toxin is an associated degree toxin discharged by the organism bacteria liable for the deadly poisoning condition referred to as food poisoning. The bacteria neurotoxins embody eight distinct subtypes known as A, B, C1, C2, D, E, F, and G. Necrolysis is wide most well-liked as an efficient mode of treatment across cosmetic and numerous therapeutic indications such as fitfulness, cervical dystonia, and chronic megrim, and others.
Botulinum Toxin Market Dynamics
Drivers
- Rising consumer preference for non-invasive procedures
Consumers have a growing preference for non-invasive procedures that offer minimal pain, quick recovery, and natural-looking results. Botulinum toxin injections align with this preference, as they provide a non-surgical alternative for cosmetic and medical treatments, driving their demand in the market. This, in turn, has carved the way for the market's growth.
- Increasing demand for cosmetic procedures
The demand for botulinum toxin in cosmetic applications, such as reducing wrinkles and fine lines, is consistently growing. As people become more conscious of their appearance and seek non-surgical options for rejuvenation, the market for botulinum toxin in cosmetic procedures continues to expand.
- Technological advancements and research initiatives
Ongoing research and technological advancements in botulinum toxin contribute to market growth. The development of novel formulations, improved delivery methods, and expanded applications of botulinum toxin drive innovation and attract healthcare professionals and patients alike.
Opportunities
- Ageing population and related conditions
Furthermore, the global population is aging, increasing the prevalence of age-related conditions like muscle stiffness, dystonia, and urinary incontinence. Botulinum toxin offers a non-surgical treatment option for these conditions, providing relief and improving the quality of life for the elderly population. The demographic shift towards an aging population is a significant driver for the botulinum toxin market and, owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, the rising internet penetration rate, increasing adoption of non-invasive cosmetic procedures, rise in the aging population globally, and increasing per capita expenditure on health care will further expand the market's growth rate in the future.
Restraints/Challenges
- High treatment cost
On the other hand, Botulinum toxin treatments can be relatively expensive, especially when multiple treatment sessions are required. The cost of treatment may be a significant barrier for some individuals, limiting the market potential, particularly in regions with lower affordability or limited healthcare coverage. Also, while botulinum toxin is generally considered safe when administered by qualified professionals, there are potential risks and adverse effects associated with its use. Concerns about possible side effects, including muscle weakness, drooping eyelids, and allergic reactions, may deter some individuals from opting for botulinum toxin treatments and are projected to challenge the market in 2022-2029.
This botulinum toxin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the botulinum toxin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In June 2022, Galderma achieved notable success in phase 3 clinical trials for its liquid formulation of botulinum toxin A, paving the way for a potential regulatory submission in the United States and other international markets. This innovative formulation eliminates the requirement for reconstitution of the aesthetic treatment from powder, offering a more convenient and streamlined approach
- In January 2021, Maypharm introduced METOX, a novel botulinum toxin formulation that effectively addresses wrinkles resulting from regular facial movements, ranging from moderate to severe. This innovative solution provides an effective method for achieving smoother skin and reducing the appearance of wrinkles
- In July 2021, AbbVie, the parent company of Allergan, announced the U.S. Food and Drug Administration (FDA) 's approval for an expanded BOTOX label. This expansion allows for treating upper limb spasticity in adults by targeting eight new muscles. The newly included muscles consist of those found in the elbow and forearm (brachialis, brachioradialis, pronator teres, and pronator quadratus), as well as intrinsic hand muscles (lumbricals and interossei) and thumb muscles (flexor pollicis brevis and opponens pollicis).
Global Botulinum Toxin Market Scope
The botulinum toxin market is segmented on the basis of type, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Botulinum Toxin A
- Botulinum Toxin B
Application
- Aesthetic
- Therapeutic
End User
- Dermatology Centers
- Hospitals and Clinics
- Others
Botulinum Toxin Market Regional Analysis/Insights
The botulinum toxin market is analysed and market size insights and trends are provided by country, type, price range, application, and end user as referenced above.
The countries covered in the botulinum toxin market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.
North America dominates the botulinum toxin market because of the strong base of advanced healthcare infrastructure, strong market demand for botulinum toxin, availability of skilled healthcare professionals, strong pharmaceutical industry presence, and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in disposable income and middle-class population, rising beauty consciousness, growing medical tourism, expansion of aesthetic clinics and medical aesthetics industry, rising aging population and changing demographics, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The botulinum toxin market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for botulinum toxin market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the botulinum toxin market. The data is available for historic period 2010-2020.
Competitive Landscape and Botulinum Toxin Market Share Analysis
The botulinum toxin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to botulinum toxin market.
Some of the major players operating in the botulinum toxin market are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- GlaxoSmithKline plc (U.K.)
- Medtronic (Ireland)
- ALLERGAN (Dublin, Ireland)
- Pfizer Inc (U.S.)
- Ipsen Pharma (France)
- UCB Pharma Ltd (U.K.)
- Sanofi (France)
- INMED PHARMACEUTICALS INC (Canada)
- Taj Pharmaceuticals Limited (India)
- Johnson & Johnson Services, Inc (U.S.)
- MediciNova, Inc (U.S.)
- Sun Pharmaceutical Industries Ltd (India)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Merz Pharma (Germany)
- GW Pharmaceuticals plc (U.K.)
- Revance Therapeutics, Inc (U.S.)
- Acorda Therapeutics, Inc (U.S.)
- HUGEL, Inc. (South Korea)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL BOTULINUM TOXIN MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL BOTULINUM TOXIN MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES DATA VOLUME
2.2.12 EPIDEMIOLOGY
2.2.13 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.14 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL BOTULINUM TOXIN MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
5.3 SYMPTOMS TYPE
5.3.1 YELLOWING OF THE SKIN
5.3.2 FATIGUE
5.3.3 WEAKNESS
5.3.4 LOSS OF APPETITE
5.3.5 ITCHING
5.3.6 EASY BRUISING
5.3.7 OTHERS
5.4 COMPLICATIONS INSIGHTS
5.4.1 EDEMA AND ASCITES
5.4.2 SPONTANEOUS BACTERIAL PERITONITIS (SBP)
5.4.3 BLEEDING FROM ESOPHAGEAL VARICES
5.4.4 HYPERSPLENISM
5.4.5 LIVER CANCER (HEPATOCELLULAR CARCINOMA)
5.4.6 HEPATIC ENCEPHALOPATHY
5.4.7 HEPATORENAL SYNDROME
5.4.8 HEPATOPULMONARY SYNDROME
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11 EPIDEMIOLOGY
11.1 INCIDENCE OF ALL BY GENDER
11.2 TREATMENT RATE
11.3 MORTALITY RATE
11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
11.5 PATIENT TREATMENT SUCCESS RATES
12 REGULATORY COMPLIANCE
12.1 REGULATORY AUTHORITIES
12.2 REGULATORY CLASSIFICATIONS
12.2.1 CLASS I
12.2.2 CLASS II
12.2.3 CLASS III
12.3 REGULATORY SUBMISSIONS
12.4 INTERNATIONAL HARMONIZATION
12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
12.6 REGULATORY CHALLENGES AND STRATEGIES
13 PIPELINE ANALYSIS
13.1 CLINICAL TRIALS AND PHASE ANALYSIS
13.2 DRUG THERAPY PIPELINE
13.3 PHASE III CANDIDATES
13.4 PHASE II CANDIDATES
13.5 PHASE I CANDIDATES
13.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR BOTULINUM TOXIN MARKET
Company Name Product Name
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR BOTULINUM TOXIN MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved but Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR BOTULINUM TOXIN MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR BOTULINUM TOXIN MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR BOTULINUM TOXIN MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
14 REIMBURSEMENT FRAMEWORK
15 OPPUTUNITY MAP ANALYSIS
16 VALUE CHAIN ANALYSIS
17 HEALTHCARE ECONOMY
17.1 HEALTHCARE EXPENDITURE
17.2 CAPITAL EXPENDITURE
17.3 CAPEX TRENDS
17.4 CAPEX ALLOCATION
17.5 FUNDING SOURCES
17.6 INDUSTRY BENCHMARKS
17.7 GDP RATION IN OVERALL GDP
17.8 HEALTHCARE SYSTEM STRUCTURE
17.9 GOVERNMENT POLICIES
17.1 ECONOMIC DEVELOPMENT
18 GLOBAL BOTULINUM TOXIN MARKET, BY TYPE
18.1 OVERVIEW
18.2 TYPE A
18.2.1 ONABOTULINUMTOXINA
18.2.2 ABOBOTULINUMTOXINA
18.2.3 INCOBOTULINUMTOXINA
18.3 TYPE B
18.4 OTHERS
19 GLOBAL BOTULINUM TOXIN MARKET, BY PRODUCT
19.1 OVERVIEW
19.2 XEOMIN
19.3 JEUVEAU
19.4 DYSPORT
19.5 BOTOX
19.6 MYOBLOC
19.7 NERBLOC
19.8 BOTULAX
19.9 OTHERS
20 GLOBAL BOTULINUM TOXIN MARKET, BY APPLICATION
20.1 OVERVIEW
20.2 THERAPEUTIC APPLICATION
20.2.1 NEUROLOGICAL DISORDERS
20.2.1.1. DYSTONIA
20.2.1.1.1. CERVICAL DYSTONIA
20.2.1.1.2. OROMANDIBULAR DYSTONIA
20.2.1.1.3. BLEPHAROSPASM
20.2.1.1.4. LARYNGEAL DYSTONIA
20.2.1.1.5. LIMB DYSTONIA
20.2.1.1.6. OROLINGUAL DYSTONIA
20.2.1.1.7. TRUNCAL DYSTONIA
20.2.1.1.8. OTHERS
20.2.1.2. NONDYSTONIC DISORDERS
20.2.1.2.1. HEMIFACIAL SPASM
20.2.1.2.2. TREMOR
20.2.1.2.3. TICS
20.2.1.2.4. MYOKYMIA AND SYNKINESIS
20.2.1.2.5. TINNITUS
20.2.1.2.6. HEREDITARY MUSCLE CRAMPS
20.2.1.2.7. NOCTURNAL BRUXISM
20.2.1.2.8. TRISMUS
20.2.1.2.9. ANISMUS
20.2.1.2.10. OTHERS
20.2.1.3. SPASTICITY
20.2.1.3.1. POST-SPINAL CORD INJURY SPASTICITY
20.2.1.3.2. CEREBRAL PALSY
20.2.1.3.3. POST-STROKE SPASTICITY
20.2.1.3.4. LOWER LIMB SPASTICITY
20.2.1.3.5. OTHERS
20.2.1.4. HEADACHE
20.2.1.4.1. CHRONIC MIGRAINE
20.2.1.4.2. TENSION-TYPE HEADACHE
20.2.1.4.3. OTHERS
20.2.1.5. OTHERS
20.2.2 DISORDER OF SECRETIONS
20.2.2.1. HYPERHIDROSIS
20.2.2.2. SIALORRHEA
20.2.2.3. OTHERS
20.2.3 DISORDERS OF THE PELVIC FLOOR
20.2.3.1. NEUROGENIC DETRUSOR OVERACTIVITY
20.2.3.2. IDIOPATHIC DETRUSOR OVERACTIVITY
20.2.3.3. OTHERS
20.2.4 OPTHALMOLOGICAL DISORDERS
20.2.4.1. STRABISMUS
20.2.4.2. DRY EYE DISEASE
20.2.4.3. OTHERS
20.2.5 GASTROINTESTINAL DISORDERS
20.2.5.1. ACHALASIA
20.2.5.2. ANAL FISSURES
20.2.5.3. SPHINCTER OF ODDI DYSFUNCTION
20.2.5.4. OTHERS
20.2.6 CHRONIC PAIN AND DISORDERS
20.2.6.1. CHRONIC LOW BACK PAIN
20.2.6.2. MYOFASCIAL PAIN SYNDROME
20.2.6.3. TENSION HEADACHE
20.2.6.4. CHRONIC MIGRAINE HEADACHE
20.2.6.5. MEDICATION OVERUSE HEADACHE
20.2.6.6. LATERAL EPICONDYLITIS
20.2.6.7. KNEE PAIN
20.2.6.8. SHOULDER PAIN
20.2.6.9. NEUROPATHIC PAIN
20.2.7 OTHERS
20.3 AESTHETIC APPLICATION
20.3.1 GLABELLAR LINES
20.3.2 LATERAL CANTHAL LINES
20.3.3 FOREHEAD LINES
20.3.4 FROWN LINES
20.3.5 OTHERS
21 GLOBAL BOTULINUM TOXIN MARKET, BY GENDER
21.1 OVERVIEW
21.2 MALE
21.3 FEMALE
22 GLOBAL BOTULINUM TOXIN MARKET, BY POPULATION TYPE
22.1 OVERVIEW
22.2 ADULTS
22.3 GERIATRIC
23 GLOBAL BOTULINUM TOXIN MARKET, BY END USER
23.1 OVERVIEW
23.2 HOSPITALS
23.2.1 BY TYPE
23.2.1.1. PUBLIC
23.2.1.2. PRIVATE
23.3 SPECIALTY CLINICS
23.3.1 BY TYPE
23.3.1.1. PUBLIC
23.3.1.2. PRIVATE
23.4 DERMATOLOGY CENTERS
23.4.1 BY TYPE
23.4.1.1. PUBLIC
23.4.1.2. PRIVATE
23.5 COSMETIC CENTERS
23.5.1 BY TYPE
23.5.1.1. PUBLIC
23.5.1.2. PRIVATE
23.6 OTHERS
24 GLOBAL BOTULINUM TOXIN MARKET, BY DISTRIBUTION CHANNEL
24.1 OVERVIEW
24.2 DIRECT TENDER
24.3 RETAIL SALES
24.3.1 HOSPITAL PHARMACY
24.3.2 RETAIL PHARMACY
24.3.3 ONLINE PHARMACY
24.3.4 OTHERS
24.4 OTHERS
25 GLOBAL BOTULINUM TOXIN MARKET, COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA PACIFIC
25.5 MERGERS & ACQUISITIONS
25.6 NEW PRODUCT DEVELOPMENT & APPROVALS
25.7 EXPANSIONS
25.8 REGULATORY CHANGES
25.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26 GLOBAL BOTULINUM TOXIN MARKET, BY GEOGRAPHY
GLOBAL PER DIEM NURSE STAFFING MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
26.1 NORTH AMERICA
26.1.1 U.S.
26.1.2 CANADA
26.1.3 MEXICO
26.2 EUROPE
26.2.1 GERMANY
26.2.2 FRANCE
26.2.3 U.K.
26.2.4 HUNGARY
26.2.5 LITHUANIA
26.2.6 AUSTRIA
26.2.7 IRELAND
26.2.8 NORWAY
26.2.9 POLAND
26.2.10 ITALY
26.2.11 SPAIN
26.2.12 RUSSIA
26.2.13 TURKEY
26.2.14 NETHERLANDS
26.2.15 SWITZERLAND
26.2.16 REST OF EUROPE
26.3 ASIA-PACIFIC
26.3.1 JAPAN
26.3.2 CHINA
26.3.3 SOUTH KOREA
26.3.4 INDIA
26.3.5 AUSTRALIA
26.3.6 SINGAPORE
26.3.7 THAILAND
26.3.8 MALAYSIA
26.3.9 INDONESIA
26.3.10 PHILIPPINES
26.3.11 VIETNAM
26.3.12 REST OF ASIA-PACIFIC
26.4 SOUTH AMERICA
26.4.1 BRAZIL
26.4.2 ARGENTINA
26.4.3 CHILE
26.4.4 PERU
26.4.5 COLOMBIA
26.4.6 VENEZUELA
26.4.7 REST OF SOUTH AMERICA
26.5 MIDDLE EAST AND AFRICA
26.5.1 SOUTH AFRICA
26.5.2 SAUDI ARABIA
26.5.3 UAE
26.5.4 EGYPT
26.5.5 KUWAIT
26.5.6 ISRAEL
26.5.7 REST OF MIDDLE EAST AND AFRICA
26.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
27 GLOBAL BOTULINUM TOXIN MARKET, SWOT AND DBMR ANALYSIS
28 GLOBAL BOTULINUM TOXIN MARKET, COMPANY PROFILE
28.1 MEDYTOX..
28.1.1 COMPANY OVERVIEW
28.1.2 REVENUE ANALYSIS
28.1.3 GEOGRAPHIC PRESENCE
28.1.4 PRODUCT PORTFOLIO
28.1.5 RECENT DEVELOPEMENTS
28.2 REVANCE AESTHETICS
28.2.1 COMPANY OVERVIEW
28.2.2 REVENUE ANALYSIS
28.2.3 GEOGRAPHIC PRESENCE
28.2.4 PRODUCT PORTFOLIO
28.2.5 RECENT DEVELOPEMENTS
28.3 IPSEN BIOPHARMACEUTICALS, INC
28.3.1 COMPANY OVERVIEW
28.3.2 REVENUE ANALYSIS
28.3.3 GEOGRAPHIC PRESENCE
28.3.4 PRODUCT PORTFOLIO
28.3.5 RECENT DEVELOPEMENTS
28.4 MERZ PHARMA
28.4.1 COMPANY OVERVIEW
28.4.2 REVENUE ANALYSIS
28.4.3 GEOGRAPHIC PRESENCE
28.4.4 PRODUCT PORTFOLIO
28.4.5 RECENT DEVELOPEMENTS
28.5 HUGHS
28.5.1 COMPANY OVERVIEW
28.5.2 REVENUE ANALYSIS
28.5.3 GEOGRAPHIC PRESENCE
28.5.4 PRODUCT PORTFOLIO
28.5.5 RECENT DEVELOPEMENTS
28.6 EVOLUS, INC
28.6.1 COMPANY OVERVIEW
28.6.2 REVENUE ANALYSIS
28.6.3 GEOGRAPHIC PRESENCE
28.6.4 PRODUCT PORTFOLIO
28.6.5 RECENT DEVELOPEMENTS
28.7 HUGEL, INC.
28.7.1 COMPANY OVERVIEW
28.7.2 REVENUE ANALYSIS
28.7.3 GEOGRAPHIC PRESENCE
28.7.4 PRODUCT PORTFOLIO
28.7.5 RECENT DEVELOPEMENTS
28.8 ALLERGAN (NOW PART OF ABBVIE)
28.8.1 COMPANY OVERVIEW
28.8.2 REVENUE ANALYSIS
28.8.3 GEOGRAPHIC PRESENCE
28.8.4 PRODUCT PORTFOLIO
28.8.5 RECENT DEVELOPMENTS
28.9 TAJ PHARMACEUTICALS LIMITED
28.9.1 COMPANY OVERVIEW
28.9.2 REVENUE ANALYSIS
28.9.3 GEOGRAPHIC PRESENCE
28.9.4 PRODUCT PORTFOLIO
28.9.5 RECENT DEVELOPMENTS
28.9.6 RECENT DEVELOPMENTS
28.1 SUPERNUS PHARMACEUTICALS
28.10.1 COMPANY OVERVIEW
28.10.2 REVENUE ANALYSIS
28.10.3 GEOGRAPHIC PRESENCE
28.10.4 PRODUCT PORTFOLIO
28.10.5 RECENT DEVELOPMENTS
28.11 CROMA PHARMA GMBH
28.11.1 COMPANY OVERVIEW
28.11.2 REVENUE ANALYSIS
28.11.3 GEOGRAPHIC PRESENCE
28.11.4 PRODUCT PORTFOLIO
28.11.5 RECENT DEVELOPMENTS
28.12 GALDERMA (NESTLÉ SKIN HEALTH)
28.12.1 COMPANY OVERVIEW
28.12.2 REVENUE ANALYSIS
28.12.3 GEOGRAPHIC PRESENCE
28.12.4 PRODUCT PORTFOLIO
28.12.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
29 RELATED REPORTS
30 CONCLUSION
31 QUESTIONNAIRE
32 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
